Prellisbio
Hayward, US · Founded 2017 · Delaware corporation · 64 employees on LinkedIn · 9 known investors
Prellis Biologics runs an antibody discovery platform that uses two-photon laser-bioprinted human immune organoids combined with machine learning to identify fully human antibody therapeutics. It develops a portfolio of antibody drug candidates across multiple disease areas and partners with biotech and pharmaceutical companies.
Founders & leadership
Prellisbio was founded in 2017 by Melanie Matheu and Noelle Mullin.
MM
Melanie MatheuCo-founder
NM
Noelle MullinCo-founder
Board
AG
Arvind GuptaBoard director
RS
Investors · 9
Black Diamond VenturesGlendale · $2M – $10M
Civilization Ventures Management, LlcTiburon · $1M – $10M
Open Field CapitalNew York
Prefix CapitalSan Francisco
Cantos VenturesreportedSan Francisco · $400K – $1.5M
Celesta CapitalreportedMenlo Park · $5M – $20M
Khosla VenturesreportedMenlo Park · $5K – $50Mvia Alex Morgan · board
SOSVreportedNew York · $30K – $550K
True VenturesreportedSan Francisco · $500K – $3Mvia Rohit Sharma · board
Reported raises · per SEC filings
Form D private placements$47.3M disclosed across 5 rounds · 2017–2022
▶$17MraisedJul 2022 · 19 investors · Other TechnologyRule 506(b)
▶$17MraisedJul 2022 · 19 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MarksDirector
- Sean O'SullivanDirector
- Melanie MatheuExecutive Officer, Director
- Alex MorganDirector
- Shaun HoltDirector
- Lei MengDirector
- Offering amount
- $35M
- Amount sold
- $17M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$19.3MraisedJul 2021 · 9 investors · Other TechnologyRule 506(b)
▶$19.3MraisedJul 2021 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Arvind GuptaDirector
- Michael MarksDirector
- Shaun HoltDirector
- Alex MorganDirector
- Melanie MatheuExecutive Officer, Director
- Offering amount
- $19.3M
- Amount sold
- $19.3M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$8.7MraisedMar 2019 · 11 investors · Other TechnologyRule 506(b)
▶$8.7MraisedMar 2019 · 11 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Melanie MatheuExecutive Officer, Director
- Rohit SharmaDirector
- Arvind GuptaDirector
- Offering amount
- $9.2M
- Amount sold
- $8.7M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$460KraisedFeb 2018 · 2 investors · BiotechnologyRule 506(b)
▶$460KraisedFeb 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arvind GuptaDirector
- Melanie MatheuExecutive Officer, Director
- Noelle MullinExecutive Officer, Director
- Rohit SharmaDirector
- Offering amount
- $1M
- Amount sold
- $460K
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.8MraisedJul 2017 · 2 investors · Other TechnologyRule 506(b)
▶$1.8MraisedJul 2017 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Noelle MullinExecutive Officer, Director
- Melanie MatheuExecutive Officer, Director
- Arvind GuptaDirector
- Rohit SharmaDirector
- Offering amount
- $2.1M
- Amount sold
- $1.8M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Fortis Life Sciences32 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Parabilis Medicines31 shared keywordsHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.
IQVIA31 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Alumis26 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Exelixis17 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with Prellisbio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Prellisbio do?
- Prellis Biologics runs an antibody discovery platform that uses two-photon laser-bioprinted human immune organoids combined with machine learning to identify fully human antibody therapeutics. It develops a portfolio of antibody drug candidates across multiple disease areas and partners with biotech and pharmaceutical companies.
- Who founded Prellisbio?
- Prellisbio was founded by Melanie Matheu, Noelle Mullin in 2017.
- Who are Prellisbio's investors?
- Prellisbio's investors include Black Diamond Ventures, Civilization Ventures Management, Llc, Open Field Capital, Prefix Capital, Cantos Ventures, Celesta Capital, Khosla Ventures, SOSV and 1 more.
- How much funding has Prellisbio raised?
- Prellisbio has disclosed $47.3M raised across 5 rounds.
- Where is Prellisbio headquartered?
- Prellisbio is headquartered in Hayward, US.